The effect of Co-administration of simvastatin and alcohol in rats

In Vivo

Volumn 17, Issue 6, 2003, Pages 523-527

  Kolovou, Genovefa D ^a   Mikhailidis, D P ^b   Daskalova, Deliana C ^a   Kafaltis, Nikolaos ^a   Adamopoulou, Evdokia N ^a   Malakos, John ^a   Bilianou, Helen G ^c   Theocharis, Stamatious E ^d   Pilatis, Nectarios D ^a   Mykoniatis, Michael G ^d   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Dyslipidaemia; Ethanol; Liver; Simvastatin; Transaminase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALCOHOL; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OLIVE OIL; PROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; WATER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DRUG ALCOHOL INTERACTION; DRUG EFFECT; DRUG SAFETY; ENZYME ACTIVITY; FEEDING; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; LIVER; LIVER DISEASE; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RAT STRAIN; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 10744228281     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Goldberg IJ, Mosca L, Piano MR, Fisher EA, Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. AHA Science Advisory: Wine and your heart: A science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. Circulation 103: 472-475, 2001.
2. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S and Breteler MB: Wine consumption and dementia in the elderly: A prospective community study in the Bordeaux area. Rev Neurol (Paris) 153: 185-192, 1997.
3. Ruitenberg A, van Swieten JC, Witteman JCM, Mehta KM, van Duijn CM, Hofman A and Breteler MMB: Alcohol consumption and risk of dementia: The Rotterdam Study. Lancet 359: 281-286, 2002.
4. Mukamal KJ, Jadhay PP, D'Agostino RB, Massaro JM, Mittleman MA, Lipinska I, Sutherland PA, Matheney T, Levy D, Wilson PWF, Ellison RC, Silbershatz H, Muller JE and Tofler GH: Alcohol consumption and hemostatic factors: Analysis of the Framingham Offspring Cohort. Circulation 104: 1367-1373, 2001.
5. Rimm EB, Klatsky A, Grobbee D and Stampfer MJ: Review of moderate alcohol consumption and reduced risk of coronary heart disease: Is the effect due to beer, wine or spirits? BMJ 312: 731-736, 1996.
6. Feiman L and Lieber CS: Ethanol and lipid metabolism. Am J Clin Nutr 70: 791-792, 1999.
7. De Oliveira E Silva ER, Foster D, McGee Harper M, Seidman CE, Smith JD, Breslow JL and Brinton EA: Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation 102: 2347-2352, 2000.
8. Papadakis JA, Ganotakis ES and Mikhailidis DP: Beneficial effect of moderate alcohol consumption on vascular disease: Myth or reality? J R Soc Health 120: 11-15, 2000.
9. Mikhailidis DP, Jeremy JY, Barradas MA, Green N and Dandona P: The effect of ethanol on vascular prostacyclin synthesis, platelet aggregation and platelet thromboxane release. Br Med J 287: 1495-1498, 1983.
10. Executive Summary of the Third Report of the National Cholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 285: 2486-2497, 2001.
11. Smith SC: Introduction. Expanding the impact of statin therapy: Would patients benefit from broader treatment and access? A Symposium: Expanding the impact of statin therapy: Would patients benefit from broader treatment and access? Am J Cardiol 85(12A): 1E-2E, 2000.
12. Kolovou G: The treatment of coronary heart disease. Statins beyond cholesterol lowering. Curr Med Res Opin 17: 34-37, 2001.
13. Kolovou G, Fostinis J, Bilianou H and Cokkinos DV: Response of high-density lipoproteins to hypolipidemic drugs according to their initial level. Am J Cardiol 75: 293-295, 1995.
14. Margeli A, Theocharis S, Skaltsas S, Skopelitou A, Kittas C, Mykoniatis M and Varonos D: Effect of cadmium pretreatment on liver regeneration after partial hepatectomy in rats. Arch Toxicol 68: 85-90, 1994.
15. Margeli AP, Skaltsas SD, Spiliopoulou CA, Mykoniatis MG and Theocharis SE: Hepatic stimulator substance activity in the liver of thioacetamide-intoxicated rats. Liver 19: 519-525, 1999.
16. Theocharis SE, Margeli AP, Agapitos EV, Mykoniatis MG, Kittas CN and Davaris PS: Effect of hepatic stimulator substance administration on tissue regeneration due to thioacetamide-induced liver injury in rats. Scand J Gastroenterol 33: 656-663, 1998.
17. Rubin E and Lieber CS: Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med 278: 869-876, 1968.
18. Lieber CS: Metabolic derangement induced by alcohol. Ann Rev Med 18: 35-54, 1967.
19. Smit JWA, Wijnne HJA, Schobben F, Sitsen A, De Bruin TWA and Erkelens DW: Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin. Am J Cardiol 76: 89A-96A, 1995.
20. Makris TM, Davydov R, Denisov IG, Hoffman BM and Sligar SC: Mechanistic enzymology of oxygen activation by the cytochromes P450. Drug Metab Rev 34: 691-708, 2002.
21. Stickel F, Seitz HK, Hahn EC and Schuppan D: Alcoholic liver disease. Gastroenterol 41: 333-342, 2003.
22. Conney AH: Pharmacological implications of microsomal enzyme inductions. Pharmacol Rev 19: 317-366, 1967.
23. Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JL and Alberts AW: Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 248: 98-505, 1989.
24. Blumenthal RS: Statins: Effective antiatherosclerotic therapy. Am Heart J 139: 577-583, 2000.
25. Blum CB: Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 73: 3D-11D, 1994.
26. Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays H, Weiss SR, Melino MR, Stepanavage ME and Mitchell YB: Efficacy and safety of simvastatin 80mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol 82: 311-316, 1998.
27. de Ledinghen V, Combes M and Winnock M: Should a liver biopsy be performed in patients with unexplained chronic abnormal ALT. Gastroenterology 116: A1201, 1999.
28. Renner EL and Dallenbach A: Increased liver enzymes: What should be done? Ther Umsch 45: 281-286, 1992.
29. Tolman KG: Defining patient risks from expanded preventive therapies. Am J Cardiol 85: 15E-19E, 2000.
30. Ginsberg H, Olefsky J, Farquhar JW and Reaven GM: Moderate ethanol ingestion and plasma triglyceride levels: A study in normal and hypertriglyceridemic persons. Ann Intern Med 80: 143-149, 1974.
31. MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW and Bokelman DL: Preclinical evaluation of lovastatin. Am J Cardiol 62: 16J-27J, 1988.
32. Stein EA, Lane M and Lanskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 81: 66B-69B, 1998.
33. Crabb DW: Pathogenesis of alcoholic liver disease: Newer mechanisms of injury. Keio J Med 48: 184-188, 1999.
34. Huang YS, Wu JC, Chang FY and Lee SD: Interleukin-8 and alcoholic liver disease. Zhoughua Yi Xue Za Zhi (Taipei) 62: 395-401, 1999.
35. McCuskey RS, Nishida J, Eguchi H, McDonnell D, Baker GL, Ekataksin W, Krasovich MA, Rudi V, Seitz HK and Urbaschek B: Role of endotoxin in the hepatic microvascular inflammatory response to ethanol. J Gastroenterol Hepatol 10(Suppl 1): S18-S23, 1995.
36. Cameron RG and Neuman MG: Novel morphologic findings in alcoholic liver disease. Clin Biochem 32: 579-584, 1999.
37. Huang YS, Chan CY, Wu JC, Pai CH, Chao Y and Lee SE: Serum levels of interleukin-8 in alcoholic liver disease relationship with disease stage biochemical parameters and survival. J Hepatol 24: 377-384, 1996.
38. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inou S and Takeshita A: Antiinflammatory and antiatherosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 89: 415-421, 2001.
39. Ridker PM, Rifai N, Pfeffer MA, Sacks F and Braunwald E: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230:235, 1999.
40. Corsini A, Bellosta S, Baetta R, Fumagalli R, Bernini F and Paoletti R: New in sights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84: 413-328, 1999.
41. Kolyada AY, Fedtsov A and Madias NE: 3-Hydroxy-3 methylglutaryl coenzyme A reductase inhibitors up-regulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension 38: 1024-1029, 2001.
42. Horsmans Y, Desager JP and Harvengt C: Biochemical changes and morphological alterations of the liver in guinea pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol 67: 336-339, 1990.
43. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M and Kuroda M: The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1254: 7-12, 1995.
44. Haslinger B, Kleemann R, Toet KH and Kooistra T: Simvastatin suppresses tissues factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int 63: 2065-2074, 2003.
45. Albert MA, Glynn RJ and Ridker PM: Alcohol consumption and plasma concentration of C-reactive protein. Circulation 107: 443-447, 2003.
46. Ok E, Yilmaz Z, Karakucuk I, Akgun H and Sahin H: Use of olive oil based emulsions as an alternative to soybean oil based emulsions in total parenteral nutrition and effects on liver regeneration following hepatic resection in Rats. Ann Nutr Metab 47: 221-227, 2003.
47. Kogire M, Inoue K, Sumi S, Doi R, Yun M, Kaji H, Higashide S and Tobe T: Effects of ethanol and wine on hepatic arterial and portal venous flows in conscious dogs. Digestion 52: 47-54, 1992.
48. Enomoto N, Yamashina S, Kono H, Schemmer P, Rivera CA, Enomoto A, Nishiura T, Nishimura T, Brenner DA and Thurman RG: Development of a new, simple rat model of early alcohol-induced liver injury based on sensitization of Kupffer cells. Hepatology 29: 1680-1689, 1999.
49. Bosma A, Seifert WF, Van Thiel-De Ruiter GC, Van Leeuwen RE, Blauw B, Roholl P, Knook DL and Brouwer A: Alcohol in combination with malnutrition causes increased liver fibrosis in rats. J Hepatol 21: 394-402, 1994.
50. Gerson RJ, Mac Donald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ and Bokelman DL: Animal safety and toxicology of simvastatin and related hydroxyl-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 87: 28S-38S, 1989.
51. Loop RA, Anthony M, Willis RA and Folkers K: Effects of ethanol, lovastatin and coenzyme Q10 treatment on antioxidants and TBA reactive material in liver of rats. Mol Aspects Med 15 (Suppl.): s195-s206, 1994.
52. Satoh T, Isobe H, Ayukawa K, Sakai H and Nawata H: The effects of pravastatin, an HMG-CoA reductase inhibitor cell viability and DNA production of rat hepatocytes. Life Sci 59: 1103-1108, 1996.
53. Thomspon CS, Strong P and Mikhailidis DP: Improvement of ketoacidosis in the diabetic rat after the administration of the oral antilipolytic agent GR79236. Clin Sci 86: 593-598, 1994.